August 20, 2017 7:14 AM ET

Healthcare Providers and Services

Company Overview of NeoGenomics Laboratories, Inc.

Company Overview

NeoGenomics Laboratories, Inc. provides cancer diagnostics and pharma services to oncologists, pathologists, pharmaceutical companies, academic centers, and others. It offers hematopathology, solid tumor, tumor profile, liquid biopsy, hereditary cancer, and women's health testing services through cytogenetic, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry and in situ hybridization, and molecular methodologies. The company also provides sarcoma fusion profile, Ewing sarcoma fusion profile, non-Ewing sarcoma fusion profile, rhabdomyosarcoma fusion profile, pediatric sarcoma fusion profile, thyroid fusion profile, human papillomavirus DNA tissue testing, brain t...

12701 Commonwealth Drive

Suite 9

Fort Myers, FL 33913

United States

Founded in 2001

Phone:

239-768-0600

Fax:

239-690-4237

Key Executives for NeoGenomics Laboratories, Inc.

Executive Chairman and Chief Executive Officer
Age: 62
Chief Financial Officer and Senior Vice President
Age: 55
Vice President of Operations
Age: 53
President of Pharma Services Division
Age: 56
President of Clinical Services Division
Age: 46
Compensation as of Fiscal Year 2017.

NeoGenomics Laboratories, Inc. Key Developments

NeoGenomics Laboratories, Inc. Enters into Credit Agreement with Regions Bank

On December 22, 2016, NeoGenomics Laboratories, Inc. as borrower, and NeoGenomics, Inc. and certain of its subsidiaries, as guarantors entered into a Credit Agreement with Regions Bank, as administrative agent and collateral agent, and the lenders party thereto. The Credit Agreement provides for a $75 million revolving credit facility and a $75 million term loan facility. The Credit Agreement provides incremental facility capacity of $50 million, subject to certain conditions. Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to an applicable margin plus, at NeoGenomics Laboratories' option, either the Adjusted LIBOR rate for the relevant interest period, an alternate base rate determined by reference to the prime lending rate of Regions, the federal funds rate for the relevant interest period plus 0.5% per annum and the one month LIBOR rate plus 1% per annum. The applicable margin will range from 2.25% to 3.50% for LIBOR loans and 1.25% to 2.50% for base rate loans, in each case based on NeoGenomics Laboratories' consolidated leverage ratio. Interest on borrowings under the Revolving Credit Facility is payable on the last day of each month, in the case of each base rate loan, and on the last day of each interest period in the case of Adjusted LIBOR loans. The Revolving Credit Facility includes a $10 million swingline sublimit, with swingline loans bearing interest at the alternate base rate plus the applicable margin. Any principal outstanding under the Revolving Credit Facility is due and payable on December 21, 2021 or such earlier date as the obligations under the Credit Agreement become due and payable pursuant to the terms of the Credit Agreement. The Term Loan Facility bears interest at a rate per annum equal to an applicable margin plus, at NeoGenomics Laboratories' option, either the Adjusted LIBOR rate for the relevant interest period, an alternate base rate determined by reference to the prime lending rate of Regions, the federal funds rate for the relevant interest period plus 0.5% per annum and the one month LIBOR rate plus 1% per annum. The applicable margin will range from 2.25% to 3.50% for Adjusted LIBOR loans and 1.25% to 2.50% for base rate loans, in each case based on NeoGenomics Laboratories' consolidated leverage ratio. Interest on the outstanding principal of the Term Loan Facility will be payable on the last day of each month, in the case of each base rate loan, and on the last day of each interest period in the case of LIBOR loans. Principal payments will be due on the last day of each fiscal quarter beginning March 31, 2017, with quarterly principal payments of approximately $0.94 million in 2017, approximately $1.41 million in 2018 and 2019, and approximately $1.88 million in 2020, with the remainder due at maturity on December 21, 2021 or such earlier date as the obligations under the Credit Agreement become due and payable pursuant to the terms of the Credit Agreement . In addition to paying interest on outstanding principal under the Credit Agreement, NeoGenomics Laboratories will be required to pay a commitment fee in respect of the unutilized portion of the commitments under the Revolving Credit Facility. The commitment fee rate will initially be 0.375% per annum, and, following the second quarter of 2017, will range from 0.25% to 0.5% depending on NeoGenomics Laboratories' consolidated leverage ratio. NeoGenomics Laboratories will also pay customary letter of credit and agency fees. The Term Loan Facility and amounts borrowed under the Revolving Credit Facility are secured pursuant to a Pledge and Security Agreement, dated December 22, 2016, among the parties identified as Obligors therein and Regions, as collateral agent on a first priority basis by a security interest in substantially all of the tangible and intangible assets of NeoGenomics Laboratories and the Guarantors. NeoGenomics Laboratories' obligations under the Credit Agreement are also guaranteed by the Guarantors.

NeoGenomics Laboratories, Inc. Presents at Craig-Hallum Capital Group 13th Annual Institutional Investor Conference, Jun-01-2016

NeoGenomics Laboratories, Inc. Presents at Craig-Hallum Capital Group 13th Annual Institutional Investor Conference, Jun-01-2016 . Venue: The Depot Renaissance Minneapolis Hotel, 225 Third Avenue South, Minneapolis, Minnesota, United States.

NeoGenomics Laboratories, Inc. Presents at 28th Annual ROTH Conference, Mar-15-2016 11:30 AM

NeoGenomics Laboratories, Inc. Presents at 28th Annual ROTH Conference, Mar-15-2016 11:30 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Drive, Laguna Niguel, Dana Point, California, United States.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1104 Welsh Road Operations LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NeoGenomics Laboratories, Inc., please visit neogenomics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.